Search Results - "Hernandez‐Ilizaliturri, F. J"

Mitochondrial protection impairs BET bromodomain inhibitor-mediated cell death and provides rationale for combination therapeutic strategies by Lasorsa, E, Smonksey, M, Kirk, J S, Rosario, S, Hernandez-Ilizaliturri, F J, Ellis, L

“…Inhibitors of the bromodomain and extraterminal domain family (BETI) have recently entered phase I clinical trials. In patients with advanced leukemia’s,…”
Get full text

P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH‐222, A NOVEL CD22‐TARGETING ANTIBODY‐DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA (R/R NHL) by Hernandez‐Ilizaliturri, F. J., Kuruvilla, J., Christian, B. A., Flinn, I. W., Assouline, S. E., Ulrickson, M. L., Landsburg, D. J., Stuart, M., Lowman, H., Levin, N., Maetzel, D., Viller, N. N., MacLaren, A.

Get full text

A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma by Witzig, T.E., Nowakowski, G.S., Habermann, T.M., Goy, A., Hernandez-Ilizaliturri, F.J., Chiappella, A., Vitolo, U., Fowler, N., Czuczman, M.S.

“…Lenalidomide is an oral non-chemotherapy immunomodulator with direct and indirect effects on non-Hodgkin lymphoma (NHL) cells and with single-agent activity in…”
Get full text

MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma by Wenzel, S-S, Grau, M, Mavis, C, Hailfinger, S, Wolf, A, Madle, H, Deeb, G, Dörken, B, Thome, M, Lenz, P, Dirnhofer, S, Hernandez-Ilizaliturri, F J, Tzankov, A, Lenz, G

“…Myeloid cell leukemia-1 (MCL1) is an anti-apoptotic member of the BCL2 family that is deregulated in various solid and hematological malignancies. However, its…”
Get full text

Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma by Straus, D.J., Duvic, M., Horwitz, S.M., Hymes, K., Goy, A., Hernandez-Ilizaliturri, F.J., Feldman, T., Wegner, B., Myskowski, P.L.

“…High response rates for doxorubicin HCl liposome injection (DLI) in cutaneous T-cell lymphoma (CTCL) have been reported with vague criteria until recently…”
Get full text

Final Result of DIAL (NCI10089), Randomized Phase 2 trial of Varlilumab combined with Nivolumab in patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma by Soekojo, C. Y., Yin, J., Kline, J., Lazaryan, A., Bartlett, N., Geethakumari, P. Ramakrishnan, Awan, F., Karmali, R., Hernandez‐Ilizaliturri, F. J., Shune, L., Lansigan, F., Reeder, C., Diefenbach, C., Sharon, E., Mikula, E., Strand, C., Postovalova, E., Kotlov, N., Zornikova, K., Bagaev, A., Fowler, N., Whitaker, K. R., Ferre, R. Leon, Costello, B. A., Yang, Z. Z., Tang, X., Ansell, S. M., Villasboas, J. C.

Get full text

Final results of phase II trial of doxorubicin HCI liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma by STRAUS, D. J, DUVIC, M, HORWITZ, S. M, HYMES, K, GOY, A, HERNANDEZ-ILIZALITURRI, F. J, FELDMAN, T, WEGNER, B, MYSKOWSKI, P. L

Get full text

Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model by Hernandez-Ilizaliturri, Francisco J., Reddy, Nishitha, Holkova, Beata, Ottman, Edris, Czuczman, Myron S.

“…New thalidomide derivatives CC-5013 and CC-4047 (immunomodulatory drugs, IMiD) are up to 10,000 times more potent than Thalidomide. The biological effects of…”
Get full text

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Soekojo, C Y, Yin, J, Kline, J, Lazaryan, A, Bartlett, N, Geethakumari, P Ramakrishnan, Awan, F, Karmali, R, Hernandez-Ilizaliturri, F J, Shune, L, Lansigan, F, Reeder, C, Diefenbach, C, Sharon, E, Mikula, E, Strand, C, Postovalova, E, Kotlov, N, Zornikova, K, Bagaev, A, Fowler, N, Whitaker, K R, Ferre, R Leon, Costello, B A, Yang, Z Z, Tang, X, Ansell, S M, Villasboas, J C

Get full text

SURVIVAL FOLLOWING FIRST RELAPSE IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA by Karmali, R., Donovan, A., Wagner‐Johntson, N., Messmer, M., Mehta, A., Anderson, J. K., Reddy, N., Kovach, A. E., Landsburg, D. J., Glenn, M., Inwards, D. J., Ristow, K., Lansigan, F., Kaplan, J. B., Caimi, P. B., Rajguru, S., Evens, A., Klein, A., Umyarova, E., Amengual, J. E., Lue, J. K., Diefenbach, C., Epperla, N., Barta, S. K., Hernandez‐Ilizaliturri, F. J, Handorf, E., Villa, D., Gerrie, A. S., Li, S., Mederios, J., Wang, M., Cohen, J., Calzada, O., Churnetski, M., Hill, B., Sawalha, Y., Gerson, J. N., Kothari, S., Vose, J. M., Bast, M., Fenske, T. S., Narayana Rao Gari, S., Maddocks, K. J., Bond, D., Bachanova, V., Kolla, B., Chavez, J., Shah, B.

Get full text

Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study by Kamdar, Manali Kirtikumar, Solomon, Scott R., Arnason, Jon, Johnston, Patrick B., Glaß, Bertram, Bachanova, Veronika, Ibrahimi, Sami, Mielke, Stephan, Mutsaers, Pim, Hernandez-Ilizaliturri, Francisco J., Izutsu, Koji, Morschhauser, Franck, Lunning, Matthew Alexander, Chow, Victor A., Santamaria, Josu, Colicino, Silvia, Ogasawara, Ken, Stepan, Lara, Abramson, Jeremy S.

“…7013 Background: Liso-cel is an autologous, CD19-directed, 4-1BB CAR T cell product. In prespecified interim and primary analyses of TRANSFORM (NCT03575351),…”
Get full text

Body mass index (BMI) and obesity as a predictor of clinical outcome in patients with Hodgkin's lymphoma treated with AVBD by Patil, R., Hernandez-Ilizaliturri, F. J., Elefante, A., Czuczman, M. S.

“…Abstract only…”
Get full text

Efficacy of combination of rituximab (R), obatoclax (O), and bortezomib (B) against rituximab-sensitive (RSCL) and rituximab-resistant B-cell lymphoma cell lines (RRCL) by Riaz, W., Hernandez-Ilizaliturri, F. J., Mavis, C., Tsai, P., Czuczman, M. S.

“…Abstract only…”
Get full text

18F-fluorodeoxglucose (FDG) positron emission tomography (PET) versus FLIPI as a predictor of therapy response in follicular lymphoma (FL) patients by Lamonica, D. M., Hahn, T., Drumsta, D., Achakzai, M., Czuczman, M. S., Hernandez-Ilizaliturri, F. J.

“…Abstract only…”
Get full text

Evaluation of carfilzomib to disrupt the apoptotic threshold of B-cell lymphomas by targeting Bcl-2 family members and overcome rituximab (R) chemotherapy resistance by Kaufman, G. P., Hernandez-Ilizaliturri, F. J., Mavis, C., Patil, R., Czuczman, M. S.

“…Abstract only…”
Get full text

ENGAGE-501: Phase II study investigating the role of epigenetic therapy with entinostat (SNDX-275) in relapsed and refractory Hodgkin's lymphoma (HL) by Younes, A., Rosen, P. J., Hernandez-Ilizaliturri, F. J., Bociek, G., Kasamon, Y. L., Copeland, A., Lee, G. T.

“…Abstract only…”
Get full text

Activity of ofatumumab (OFA), a fully human monoclonal antibody targeting CD20, against rituximab (RTX)-sensitive (RSCL) and rituximab-resistant cell lines (RRCL), in vivo, and primary tumor cells derived from patients with B-cell lymphoma by Barth, M. J., Hernandez-Ilizaliturri, F. J., Mavis, C., Tsai, P., Gibbs, J. F., Czuczman, M. S.

“…Abstract only…”
Get full text

Strategies to overcoming rituximab-chemotherapy resistance by targeting the autophagy pathway using bortezomib in combination with the Bcl-2 inhibitor obatoclax in non-Hodgkin's lymphomas (NHL) by Hernandez-Ilizaliturri, F. J., Khubchandani, S., Olejniczak, S. H., Hoskin, P., Czuczman, M. S.

“…Abstract only 8543 We found that repeated rituximab exposure leads to deregulation of Bcl-2 proteins and concomitant chemotherapy resistance. We demonstrated…”
Get full text

Abrogation of tumor necrosis alpha (TNF-alpha) pathway by anti-TNF therapy in hematological malignancies by Ramanarayanan, J., Pahuja, S., Elefante, A. N., Hernandez-Ilizaliturri, F. J.

“…Abstract only 7093 Background: Tumor necrosis factor-alpha (TNF-alpha) enhances tumor growth and mediates cancer-related inflammatory symptoms by inducing…”
Get full text

Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib by Maraj, I., Hernandez-Ilizaliturri, F. J., Chisti, M., Czuczman, M. S.

“…Abstract only 8576 Deacetylases (DACs) are enzymes that remove the acetyl groups from target proteins [histones (class I) and non-histones (class II)], leading…”
Get full text